Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell

Jane Houldsworth1, Adam B Olshen, Giorgio Cattoretti

  • 1Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

Blood
|November 15, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

Blood advances·2026
Same author

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026
Same author

Distinct neuronal, proliferative, and secretory pathways are perturbed in cancer survivors with depressive symptoms.

medRxiv : the preprint server for health sciences·2026
Same author

Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

Blood·2026
Same author

Precision Medicine in a Patient With Multiple Myeloma Presenting With t(2;11) and <i>CCND1</i> Overexpression.

EJHaem·2026
Same author

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in <i>TP53</i>-Mutated Diffuse Large B-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Amplification of the REL gene locus in diffuse large B-cell lymphoma (DLBCL) does not appear to increase REL protein activity. DLBCLs show heterogeneity in REL and nuclear factor-kappaB (NF-kappaB) activity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The 2p12-16 chromosomal region amplification is observed in diffuse large B-cell lymphoma (DLBCL).
  • The REL gene, encoding a transcription factor, has been proposed as the critical target of this amplification.
  • Experimental validation of REL's role in DLBCL pathogenesis is limited.

Purpose of the Study:

  • To investigate the association between REL gene amplification and REL protein function in DLBCL.
  • To correlate REL amplification and activity with DLBCL molecular subgroups and clinical features.

Main Methods:

  • Analysis of REL gene copy number in 46 newly diagnosed DLBCL samples.
  • Immunofluorescence to assess the accumulation of the active form of REL protein.
  • Gene expression profiling to subgroup DLBCL cases.

Related Experiment Videos

  • Correlation analysis with clinical parameters.

    • Main Results:

    • REL locus amplification was detected across all DLBCL subgroups.
    • Amplification did not correlate with increased levels of active REL protein.
    • High nuclear REL levels were more prevalent in the activated B-cell-like DLBCL subgroup.
    • No significant association was found between REL copy number or nuclear accumulation and clinical parameters.

    Conclusions:

    • The 2p12-16 amplification in DLBCL does not seem to result in abnormal REL activation.
    • REL may not be the direct functional target of the 2p12-16 amplification event.
    • DLBCL exhibits heterogeneity in REL expression and nuclear factor-kappaB (NF-kappaB) pathway activity.